Get the Stockscreener App
27.53
2.47%
-0.77
Sensei Biotherapeutics Inc stock is traded at $27.53, with a volume of 29,689.
It is down -2.47% in the last 24 hours and up +9.83% over the past month.
Sensei Biotherapeutics Inc is a clinical-stage biotechnology company engaged in the development of therapies targeting cancer through multi-node inhibition of oncogenic pathways. The company's lead program, PIKTOR, is an investigational oral combination therapy designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway and is being evaluated for the treatment of endometrial and breast cancers. In addition, the company is advancing other pipeline programs targeting tumor metabolism and signaling pathways.
See More
Previous Close:
$28.30
Open:
$28.773
24h Volume:
29,689
Relative Volume:
0.11
Market Cap:
$36.34M
Revenue:
-
Net Income/Loss:
$-24.14M
P/E Ratio:
-1.9685
EPS:
-13.985
Net Cash Flow:
$-22.40M
1W Performance:
-15.39%
1M Performance:
+9.83%
6M Performance:
+191.90%
1Y Performance:
+242.43%
1-Day Range:
$27.09
$28.77
1-Week Range:
$26.31
$32.40
52-Week Range:
$5.25
$36.76
Sensei Biotherapeutics Inc Stock (SNSE) Company Profile
Name
Sensei Biotherapeutics Inc
Sector
Industry
Phone
(240) 243-8000
Address
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare SNSE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNSE
Sensei Biotherapeutics Inc
|
27.09 | 39.04M | 0 | -24.14M | -22.40M | -13.98 |
VRTX
Vertex Pharmaceuticals Inc
|
428.14 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
706.09 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.98 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.84 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
296.74 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sensei Biotherapeutics Inc Stock (SNSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Initiated | Leerink Partners | Outperform |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-01-21 | Downgrade | Berenberg | Buy → Hold |
| Jun-29-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-01-21 | Initiated | Berenberg | Buy |
| Mar-01-21 | Initiated | Citigroup | Buy |
| Mar-01-21 | Initiated | Oppenheimer | Outperform |
| Mar-01-21 | Initiated | Piper Sandler | Overweight |
View All
Sensei Biotherapeutics Inc Stock (SNSE) Latest News
[144] Sensei Biotherapeutics, Inc. SEC Filing - Stock Titan
Sensei Biotherapeutics (SNSE) price target increased by 53.85% to 51.00 - MSN
Sensei Biotherapeutics (NASDAQ: SNSE) registers 24.87M resale shares - Stock Titan
Faeth-focused recapitalization at Sensei (NASDAQ: SNSE) reshapes ownership and adds $200M - Stock Titan
Is Sensei Biotherapeutics (SNSE) stock a favorable investment idea | Q4 2025: EPS Exceeds ExpectationsCrowd Breakout Signals - Xã Thanh Hà
Is Sensei Biotherapeutics (SNSE) stock facing investor skepticism | Q4 2025: Earnings Beat EstimatesHot Momentum Watchlist - Cổng thông tin điện tử tỉnh Lào Cai
Is Sensei Biotherapeutics (SNSE) stock relatively low risk (Market Focus) 2026-04-22High Beta Stocks - Xã Vĩnh Công
Sensei Biotherapeutics Inc Live Share Prices and Trades. SNSE.US Live Streaming Share Prices. - London South East
Leerink initiates Sensei Biotherapeutics stock at Outperform, $50 target By Investing.com - Investing.com South Africa
Leerink initiates Sensei Biotherapeutics stock at Outperform, $50 target - Investing.com
Sensei Biotherapeutics: If Proposals Are Approved, COO Anand Parikh Is Expected to Become CEO - Moomoo
Sensei Biotherapeutics Announces Leadership and Board Transitions - TipRanks
Christopher W. Gerry, Thomas Ricks, and Kristian Humer Tender Conditional Resignations From Sensei Biotherapeutics Board, Effective in June - Moomoo
Leadership and board overhaul outlined by Sensei Biotherapeutics (NASDAQ: SNSE) - Stock Titan
Faeth deal shifts control; Sensei Biotherapeutics (NASDAQ: SNSE) seeks shareholder approvals - Stock Titan
Form 8-K/ACurrent report: [Amend] - ADVFN
Sensei Biotherapeutics (SNSE) details Faeth acquisition, PIPE and going-concern warning - Stock Titan
Sensei Biotherapeutics (SNSE) grants PFO 80,000 stock options - Stock Titan
Director at Sensei Biotherapeutics (SNSE) receives 23,100 stock options - Stock Titan
Sensei Biotherapeutics Inc and Faeth Therapeutics Acquisition Call Transcript - GuruFocus
Macro Review: Is Sensei Biotherapeutics Inc in a bullish channel2026 Trading Recap & Community Consensus Trade Signals - baoquankhu1.vn
Sensei Biotherapeutics Halts Lead Drug Development, Explores Sale Or Merger Options - MSN
Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - BioSpace
Aug Update: What is the Moat Score of Sensei Biotherapeutics IncQuarterly Market Summary & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Should I Buy Sensei Biotherapeutics (SNSE) Stock Today | Price at $33.00, Up 6.38%Elite Alerts - Xã Thanh Hà
Investor Mood: What is the Moat Score of Sensei Biotherapeutics IncQuarterly Profit Summary & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Sidley Represents Sensei Biotherapeutics in Acquisition of Faeth Therapeutics - Legal Desire Media and Insights
AI Stocks: Can Sensei Biotherapeutics Inc grow without dilution2026 Catalysts & Trade Opportunity Analysis Reports - baoquankhu1.vn
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update - biospace.com
Sensei Biotherapeutics (SNSE) Sets Ambitious Clinical Goals for 2026 - GuruFocus
Faeth acquisition and $200M raise reshape Sensei Biotherapeutics (NASDAQ: SNSE) - stocktitan.net
Sensei Biotherapeutics Acquires Faeth, Advances PIKTOR Cancer Program with $200M Financing and Reports 2025 Financial Results - Minichart
Sensei Biotherapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sensei Biotherapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update - TradingView
Sensei Biotherapeutics (NASDAQ: SNSE) 2025 loss narrows, lands $200M - Stock Titan
Aug Chart Watch: What is Sensei Biotherapeutics Incs TAM Total Addressable Market2026 WrapUp & Real-Time Market Trend Scan - baoquankhu1.vn
If You Invested $1,000 in Sensei Biotherapeutics, Inc. (SNSE) - Stock Titan
Decliners Report: Does Sensei Biotherapeutics Inc have pricing power2026 Sector Review & Long-Term Safe Investment Plans - baoquankhu1.vn
Aug Technicals: What is the Moat Score of Sensei Biotherapeutics Inc2026 PreEarnings & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Momentum Shift: Can Sensei Biotherapeutics Inc be the next market leaderWeekly Profit Recap & Capital Efficient Trade Techniques - baoquankhu1.vn
SNSE.O PE Ratio & Valuation, Is SNSE.O Overvalued - Intellectia AI
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology - GlobeNewswire Inc.
Anand Kiran Parikh Net Worth (2026) - GuruFocus
Sensei Biotherapeutics announces inducement grants under Nasdaq listing rule - TipRanks
Sensei Biotherapeutics (SNSE) Announces Stock Option Grant to Ne - GuruFocus
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PharmiWeb.com
Sensei Biotherapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Why Sensei Biotherapeutics Inc. stock is favored by pension funds2026 Pullbacks & Reliable Entry Point Trade Alerts - Naître et grandir
Update Recap: How buybacks impact Sensei Biotherapeutics Inc. stock valueCEO Change & Comprehensive Market Scan Insights - Naître et grandir
Published on: 2026-03-07 01:25:22 - Naître et grandir
Sensei Biotherapeutics Inc Stock (SNSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):